Drugs / OSUNPROTAFIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04777994 | Mar 2021 → Oct 2026 expected | — | Calico Life Sciences LLC | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06188975 Background | — | — | Calico Life Sciences LLC | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-04 | Calico Life Sciences LLC | Results Nature Publishes Discovery and Preclinical Results for ABBV-CLS- 484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy calicolabs.com ↗
The findings, based on research conducted by AbbVie in collaboration with the Broad Institute and Calico, support the development of ABBV-CLS-484 as a promising new strategy for cancer immunotherapy. |
| 2023-10-04 | AbbVie | Results Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy abbvie.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSUNPROTAFIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095164 ↗ |
| Known as | ABBV-CLS-484 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04777994 ↗ |
| Known as | AC484 | “Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor.” PMID 37794185 ↗ Oct 2023 |
| Action | Inhibit | “Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor.” PMID 37794185 ↗ Oct 2023 |
| Modality | Small molecule | “More broadly, our study shows that small-molecule inhibitors of key intracellular immune regulators can achieve efficacy comparable to or exceeding that of antibody-based...” PMID 37794185 ↗ Oct 2023 |
| Route | Oral | “Oral Capsule” NCT04777994 ↗ |
| Target | PTPN1 | “Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor.” PMID 37794185 ↗ Oct 2023 |
| Target | PTPN2 | “Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor.” PMID 37794185 ↗ Oct 2023 |